The estimated Net Worth of Charles J Homcy is at least $52.2 Million dollars as of 16 February 2024. Charles Homcy owns over 3,760 units of BridgeBio Pharma Inc stock worth over $34,472,316 and over the last 20 years he sold BBIO stock worth over $11,752,544. In addition, he makes $5,975,840 as Chairman of Pharmaceuticals and Lead Director at BridgeBio Pharma Inc.
Charles has made over 30 trades of the BridgeBio Pharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 3,760 units of BBIO stock worth $105,242 on 16 February 2024.
The largest trade he's ever made was exercising 120,803 units of BridgeBio Pharma Inc stock on 23 June 2017 worth over $604,015. On average, Charles trades about 14,819 units every 49 days since 2005. As of 16 February 2024 he still owns at least 1,231,594 units of BridgeBio Pharma Inc stock.
You can see the complete history of Charles Homcy stock trades at the bottom of the page.
Dr. Charles J. Homcy M.D. serves as Chairman of Pharmaceuticals, Lead Director of the Company. Charles Homcy, M.D. has served as a member of our Board of Directors since November 2018, our Chairman of Pharmaceuticals since February 2019, and our Lead Director since February 2020. In 2010, Dr. Homcy joined Third Rock Ventures, a venture capital firm, where he is currently a partner. He served as president and chief executive officer of Portola Pharmaceuticals, a clinical biotechnology company, and he served as their president and chief executive officer since co-founding the company in 2003 until 2010. Prior to that, Dr. Homcy served as the president of research and development at Millennium Pharmaceuticals, Inc. (currently, Takeda Oncology), a biopharmaceutical company, following its acquisition of COR Therapeutics, Inc. in 2002. He joined COR Therapeutics, Inc., a biopharmaceutical company, in 1995 as executive vice president of research and development, and he served as a director of the company from 1998 to 2002. Dr. Homcy was a clinical professor of medicine at the University of California, San Francisco Medical School, and attending physician at the San Francisco Veterans Affairs Hospital from 1997 to 2011. He was previously president of the medical research division of American Cyanamid-Lederle Laboratories, a division of Wyeth-Ayest Laboratories. He currently serves on the board of directors of Portola Pharmaceuticals, Inc. (Nasdaq: PTLA), a position he has held since 2004, and of Global Blood Therapeutics, Inc. (Nasdaq: GBT). Dr. Homcy holds a B.A. and an M.D. from Johns Hopkins University and currently serves on its board of trustees. Dr. Homcy’s qualifications to serve on our Board of Directors include his significant experience building and leading successful biotechnology companies and his scientific expertise.
As the Chairman of Pharmaceuticals and Lead Director of BridgeBio Pharma Inc, the total compensation of Charles Homcy at BridgeBio Pharma Inc is $5,975,840. There are 1 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.
Charles's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo, and Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: